Previous 10 | Next 10 |
2023-08-14 17:28:16 ET Emmaus Life Sciences press release ( OTCQX:EMMA ): Q2 GAAP EPS of -$0.03. Revenue of $10.8M (+152.3% Y/Y). For further details see: Emmaus Life Sciences GAAP EPS of -$0.03, revenue of $10.8M
Emmaus Life Sciences Reports Q2 2023 Financial Results PR Newswire Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues TORRANCE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences,...
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman PR Newswire Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif. , July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA)...
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA PR Newswire TORRANCE, Calif. , May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that...
2023-05-16 04:11:46 ET Emmaus Life Sciences press release ( OTCQX:EMMA ): Q1 GAAP EPS of -$0.07. Revenue of $6.8M (+110.5% Y/Y) beats by $1.8M . On March 31, 2023, the company had cash and cash equivalents of $1.8 million, compared with $2.0 million on December 31, 202...
2023-05-15 10:52:34 ET Those afflicted with sickle cell disease face many challenges and acute complications. This %Biopharma company is the leader in treatment of the disease and just reported its fifth straight increase in quarterly net revenues. %EmmausLifeSciences (OTC: $EMM...
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update PR Newswire TORRANCE, Calif. , May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treat...
Emmaus Life Sciences Provides Interim Shipment Data PR Newswire TORRANCE, Calif. , April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended ...
2023-04-03 01:09:23 ET Emmaus Life Sciences press release ( OTCQX:EMMA ): FY GAAP EPS of -$0.21. Revenue of $18.39M (-10.8% Y/Y). For further details see: Emmaus Life Sciences GAAP EPS of -$0.21, revenue of $18.39M
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update PR Newswire TORRANCE, Calif. , March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical company and leader in the treat...
News, Short Squeeze, Breakout and More Instantly...
Emmaus Life Sciences Incorporation Company Name:
EMMA Stock Symbol:
NYSE Market:
Emmaus Life Sciences Incorporation Website:
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program PR Newswire TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceuti...
Emmaus Life Sciences Reports 2023 Financial Results PR Newswire TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today r...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...